Journal of Prevention and Treatment for Stomatological Diseases ›› 2019, Vol. 27 ›› Issue (1): 50-55.doi: 10.12016/j.issn.2096-1456.2019.01.010

• Review Articles • Previous Articles     Next Articles

Research progress on the treatment of oral and maxillofacial hemangioma

DENG Jiaxin1,CHEN Yue1,CHEN Yuan1,WANG Yan2()   

  1. 1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu 610041, China
    2. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, Dept. of Pediatric Dentistry West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2018-06-23 Revised:2018-08-23 Online:2019-01-20 Published:2019-01-22
  • Contact: Yan WANG E-mail:wangyan1458@163.com

Abstract:

Hemangioma is the most common vascular benign tumor in infants and young children, 60% of which occur in the oral maxillo-facial region. One characteristic of oral and maxillofacial hemangioma is spontaneous regression, which generally does not require treatment; however, a few hemangiomas can produce complications including ulceration, functional disorders and dis?gurement, which require active treatments. Currently, the treatment of oral and maxillofacial hemangioma include drug treatment, laser treatment and surgical treatment. The drugs used to treat hemangioma mainly include beta blockers, glucocorticoids, alpha-interferon, imiquimod and antitumor drugs. Drug therapy is suitable for multiple, rapidly proliferating hemangiomas and hemangiomas that affect vital organ function or endanger life. Laser therapy can be applied to the early treatment of rapidly growing hemangiomas at exposed sites. Surgical treatment is suitable for proliferative hemangioma with serious complications, the reconstruction of any external deformity and the repair of a scar after an ulcer. Combined therapy and the development of new technologies provide new directions for the treatment of hemangioma but the efficacy remains to be proven by large sample prospective studies. Clinicians should appropriately evaluate the patients with hemangioma and develop individualized treatment programs for patients with treatment indications. This article reviews the efficacy, mechanism, clinical application and adverse reactions of different treatment methods and provides references for clinical treatment.

Key words: Oral and maxillofacial region, Hemangioma, Beta blocker, Propranolol, Glucocorticoid, Laser treatment, Infants and young children

CLC Number: 

  • R739.8
[1] Hoeger PH, Harper JI, Baselga E , et al. Treatment of infantile haemangiomas: recommendations of a European expert group[J]. Eur J Pediatr, 2015,174(7):855-865.
doi: 10.1007/s00431-015-2570-0
[2] Hassani A, Saadat S, Moshiri R , et al. Hemangioma of the buccal fat pad[J]. Contemp Clin Dent, 2014,5(2):243-246.
doi: 10.4103/0976-237X.132368
[3] Abraham A, Job AM, Roga G . Approach to infantile hemangiomas[J]. Indian J Dermatol, 2016,61(2):181-186.
doi: 10.4103/0019-5154.177755
[4] Chen TS, Eichenfield LF, Friedlander SF . Infantile hemangiomas: an update on pathogenesis and therapy[J]. Pediatrics, 2013,131(1):99-108.
doi: 10.1542/peds.2012-1128
[5] Zheng JW, Zhang L, Zhou Q , et al. A practical guide to treatment of infantile hemangiomas of the head and neck[J]. Int J Clin Exp Med, 2013,6(10):851-860.
[6] Mull JL, Chamlin SL, Lai JS , et al. Utility of the hemangioma severity scale as a triage tool and predictor of need for treatment[J]. Pediatr Dermatol, 2017,34(1):78-83.
doi: 10.1111/pde.2017.34.issue-1
[7] Park YW, Yeom KB, Choi JW , et al. Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience[J]. J Dermatol Treat, 2014,25(5):391-395.
doi: 10.3109/09546634.2012.761667
[8] Lou Y, Peng WJ, Cao Y , et al. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies[J]. Br J Clin Pharmacol, 2014,78(1):44-57.
doi: 10.1111/bcp.2014.78.issue-1
[9] Ji Y, Chen S, Xu C , et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action[J]. Br J Dermatol, 2015,172(1):24-32.
doi: 10.1111/bjd.2015.172.issue-1
[10] Tu JB, Ma RZ, Dong Q , et al. Induction of apoptosis in infantile hemangioma endothelial cells by propranolol[J]. Exp Ther Med, 2013,6(2):574-578.
doi: 10.3892/etm.2013.1159
[11] Marqueling AL, Oza V, Frieden IJ , et al. Propranolol and infantile hemangiomas four years later: a systematic review[J]. Pediatr Dermatol, 2013,30(2):182-191.
doi: 10.1111/pde.12089
[12] Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J , et al. A randomized, controlled trial of oral propranolol in infantile hemangioma[J]. N Engl J Med, 2015,372(8):735-746.
doi: 10.1056/NEJMoa1404710
[13] Léaute-Labrèze CЁ, Boccara O, Degrugillier-Chopinet C , et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review[J]. Pediatrics, 2016,138(4):20160353
doi: 10.1542/peds.2016-0353
[14] Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F , et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study[J]. J Am Acad Dermatol, 2014,70(6):1045-1049.
doi: 10.1016/j.jaad.2014.01.905
[15] Alexopoulos A, Thanopoulou I, Dakoutrou M , et al. Atenolol treatment for severe infantile hemangiomas: a single-centre prospective study[J]. J Eur Acad Dermatol Venereol, 2018,32(3):117-119.
doi: 10.1111/jdv.2018.32.issue-1
[16] Villalba-Moreno AM, Cotrina-Luque J, Del Vayo-Benito CA , et al. Nadolol for the treatment of infantile hemangioma[J]. Am J Health Syst Pharm, 2015,72(1):44-46.
doi: 10.2146/ajhp140097
[17] Puttgen K, Lucky A, Adams D , et al. Topical timolol maleate treatment of infantile hemangiomas[J]. Pediatrics, 2016, 138(3): pii: e20160355. doi: 10.1542/peds.
doi: 10.1542/peds.2016-0355
[18] Painter SL, Hildebrand GD . Review of topical beta blockers as treatment for infantile hemangiomas[J]. Surv Ophthalmol, 2016,61(1):51-58.
doi: 10.1016/j.survophthal.2015.08.006
[19] Khan M, Boyce A, Prieto-Merino D , et al. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis[J]. Acta Derm Venereol, 2017,97(10):1167-1171.
doi: 10.2340/00015555-2681
[20] Küpeli S . Evolving strategy in treatment of infantile hemangiomas: from steroids to propranolol[J]. Cukurova Med J, 2016,41(2):354-359.
doi: 10.17826/cutf.201781
[21] Izadpanah A, Izadpanah A, Kanevsky J , et al. Propranolol versuscorticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis[J]. Plast Reconstr Surg, 2013,131(3):601-613.
doi: 10.1097/PRS.0b013e31827c6fab
[22] Theunissen C, Smitt JH, Van der horst CM . Propranolol versus corticosteroids: what should be the treatment of choice in infantile hemangiomas[J]. Ann Plast Surg, 2015,74(2):237-241.
doi: 10.1097/SAP.0b013e318299cd4e
[23] Zhang L, Zheng JW, Yuan WE . Treatment of alarming head and neck infantile hemangiomas with interferon-α2a: a clinical study in eleven consecutive patients[J]. Drug Des Devel Ther, 2015,9:723-727.
[24] Qiu Y, Ma G, Yang J , et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study[J]. Clin Exp Dermatol, 2013,38(8):845-850.
doi: 10.1111/ced.2013.38.issue-8
[25] 郑家伟, 马坤宁, 张凌 . 婴幼儿血管瘤药物治疗概述[J]. 中国口腔颌面外科杂志, 2014,12(1):1-6.
[26] Hou J, Wang M, Tang H , et al. Pingyangmycin sclerotherapy for infantile hemangiomas in oral and maxillofacial regions: an evaluation of 66 consecutive patients[J]. Int J Oral Maxillofac Surg, 2011,40(11):1246-1251.
doi: 10.1016/j.ijom.2011.07.906
[27] Michelle SN. Yong-Kwang T . Laser treatment of infantile hemangiomas[J]. Indian J Paediatr Dermatol, 2017,18(3):160-165.
doi: 10.4103/ijpd.IJPD_108_16
[28] Kwon SH, Choi JW, Byun SY , et al. Effect of early long-pulse pulsed dye laser treatment in infantile hemangiomas[J]. Dermatol Surg, 2014,40(4):405-411.
doi: 10.1111/dsu.12451
[29] Chinnadurai S, Sathe NA, Surawicz T . Laser treatment of infantile hemangioma: a systematic review[J]. Lasers Surg Med, 2016,48(3):221-233.
doi: 10.1002/lsm.v48.3
[30] Lee AH, Hardy KL, Goltsman D , et al. A retrospective study to classify surgical indications for infantile hemangiomas[J]. J Plast Reconstr Aesthet Surg, 2014,67(9):1215-1221.
doi: 10.1016/j.bjps.2014.05.007
[31] Goldenberg DC, Hiraki PY, Marques TM , et al. Surgical treatment of facial infantile hemangiomas: an analysis based on tumor characteristics and outcomes[J]. Plast Reconstr Surg, 2016,137(4):1221-1231.
doi: 10.1097/PRS.0000000000002016
[32] Zhu ZY, Yang XL, Zhao YE , et al. Early surgical management of large scalp infantile hemangioma using the top closure tension-relief system[J]. Medicine (Baltimore), 2015,94(47):e2128.
doi: 10.1097/MD.0000000000002128
[33] Alsmman AH, Mounir A . Combined oral propranolol with intralesional injection of triamcinolone acetonide in treatment of infantile periocular hemangiomas[J]. Clin Ophthalmol, 2017,11:2177-2181.
doi: 10.2147/OPTH
[34] Ma G, Wu P, Lin X , et al. Fractional Carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: a pilot study[J]. Pediatr Dermatol, 2014,31(3):286-291.
doi: 10.1111/pde.2014.31.issue-3
[35] Furuta S, Sato H, Tsuji S , et al. Effective treatment for infantile hemangioma with long-pulsed dye laser with oral propranolol medication: a preliminary report[J]. Pediatr Surg Int, 2016,32(9):857-862.
doi: 10.1007/s00383-016-3942-x
[36] Kaune KM, Lauerer P, Kietz S , et al. Combination therapy of infantile hemangiomas with pulsed dye laser and Nd:YAG laser is effective and safe[J]. J Dtsch Dermatol Ges, 2014,12(6):473-478.
[37] 凌冰, 陈东民, 周平 , 等. 介入栓塞治疗颌面部血管瘤的临床应用[J]. 医学影像学杂志, 2012,23(12):2098-2099.
[38] Haddy N, Mousannif A, Paoletti C , et al. Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma[J]. Melanoma Res, 2012,22(1):77-85.
doi: 10.1097/CMR.0b013e32834dcff1
[1] SU Weizhe, FAN Yawei, MENG Bing. Research status of IgG4-related sialadenitis [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2020, 28(1): 56-60.
[2] Hao LUO,Jian MENG. IgG4-related Mikulicz disease: a case report and literature review [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(7): 468-471.
[3] ZHENG Jiawei,ZHAO Zeliang. Progress in the genetics research of infantile hemangioma and vascular malformations [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(12): 749-756.
[4] LI Jiapeng,CHEN Jufeng,ZHANG Guorun,XIAN Dan,LI Jin,WANG Lei,ZHANG Guoyi. Study of the therapeutic effect of oral propranolol combined with topical timolol maleate in the treatment of mixed maxillofacial hemangioma in infants [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2019, 27(11): 718-722.
[5] Xiao'an TAO, Bin CHENG. The present situation in treatment for oral lichen planus [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(3): 143-150.
[6] Longjiang LI, Bo HAN. Optimized reconstruction of oral and maxillofacial defects with common soft-tissue free flaps [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(3): 137-142.
[7] Xiao-ping WU,Da-ming ZHANG,Wei-liang CHEN. Clinical observation of treating infantile head and neck hemangioma with oral propranolol [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(3): 158-161.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Chao TANG,Jing SUN,Ju-feng CHEN. Influence of nursing intervention on the life quality of patients with tongue cancer after operation[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(3): 177 -179 .
[2] Hong-chang LAI,Jun-yu SHI. Maxillary sinus floor elevation[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(1): 8 -12 .
[3] WANG An-xun. Research progress on the invasion and metastasis of tongue squamous cell carcinoma[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2016, 24(5): 261 -266 .
[4] Pin ZHOU, Yang-fei LI. MRI study of temporomandibular joint disc position in asymptomatic volunteers[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(4): 239 -244 .
[5] Xinxin XIA, Fang FANG, Lijuan CHENG. Shaping ability of Pathfile and WaveOne in simulated root canals[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(6): 365 -368 .
[6] Yuanhong LI, Xinyi FANG, Yu QIU, Lei CHENG. Experimental study on the effects of green tea on salivary flow rate and pH value[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(9): 560 -564 .
[7] Chengzhang LI. Masticatory muscles in occlusion[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2017, 25(12): 755 -760 .
[8] . [J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(1): 1 .
[9] Zhirong WU, Shiguang Huang. Research progress on the etiology, clinical examination and treatment of peri-implantitis[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(6): 401 -405 .
[10] Xiaowu YAO, Shisheng CHEN, Zizheng LU, Minxiao LIN. Clinical report and literature review on the amyloidosis of salivary glands[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2018, 26(8): 533 -536 .
This work is licensed under a Creative Commons Attribution 3.0 License.